Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Jeet will be a trusted partner in cardiovascular care
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Call it a major breakthrough for diagnostic imaging
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Subscribe To Our Newsletter & Stay Updated
